NeoGenomics Unveils RaDaR ST Liquid Biopsy MRD Assay for Solid Tumor Detection
I'm PortAI, I can summarize articles.
NeoGenomics Inc. has announced the presentation of new research at the ISLB Annual Congress 2025, showcasing results from the RaDaR ST Bridging Study, which indicates high concordance between its RaDaR ST and RaDaR 1.0 assays for detecting molecular residual disease in solid tumors. The company will also discuss its NextGen whole genome-based MRD research program and findings from four additional studies. The RaDaR ST assay is expected to launch commercially in Q1 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments